Felipe
Prosper Cardoso
Consultor Médico
Hospital Universitario 12 de Octubre
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (30)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Modulation of tumor microenvironment by targeting histone acetylation in bladder cancer
Cell Death Discovery, Vol. 10, Núm. 1
-
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
Leukemia
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models
Biomedicine and Pharmacotherapy, Vol. 150
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
Frontiers in Oncology, Vol. 12
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression
Journal of Urology
-
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
Leukemia, Vol. 34, Núm. 2, pp. 589-603
-
Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib
Journal of Pathology, Vol. 252, Núm. 1, pp. 29-40
2019
2017
-
Differentiation stage of myeloma plasma cells: Biological and clinical significance
Leukemia, Vol. 31, Núm. 2, pp. 382-392
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
-
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136